Breaking Finance News

A statement released earlier today by Suntrust Robinson about Clovis Oncology Inc (NASDAQ:CLVS) bumps the target price to $50.00

Boasting a price of $38.64, Clovis Oncology Inc (NASDAQ:CLVS) traded 2.06% higher on the day. The last closing price is up 124.39% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $23.50 and a 200-day moving average of $17.45. 930,748 shares of the stock were exchanged, down from an average trading volume of 2,551,230

Suntrust Robinson bumped up the target of Clovis Oncology Inc (NASDAQ:CLVS) to $50.00 stating a potential upside of 0.29%.

See Chart Below

Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology Inc has a 52 week low of $11.57 and a 52 week high of $109.18 Clovis Oncology Inc’s market capitalization is presently $0.

A total of 8 brokerages have issued a ratings update on Clovis Oncology Inc. Two brokerages rating the company a strong buy, zero brokerages rating the company a buy, six brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $17.50.

General Company Details For Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *